From: The role of immune checkpoint inhibition in the treatment of ovarian cancer
 |  | % Total for histologic subtype | |||
---|---|---|---|---|---|
Histologic subtype | N | Type I | Type II | Type III | Type IV |
High-grade serous | 112 | 57.4 | 5.1 | 0 | 37.4 |
Low-grade serous | 11 | 0 | 9.1 | 0 | 90.9 |
Mucinous | 30 | 26.7 | 16.7 | 0 | 56.7 |
Endometrioid | 125 | 22.4 | 14.4 | 1.6 | 61.6 |
Clear cell | 129 | 16.2 | 30.2 | 0 | 53.5 |